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Abstract
Background: Live birth has increasingly been identified as the standard clinical approach to measure the success
of medically assisted reproduction (MAR). However, previous analyses comparing biosimilar preparations of
follitropin alfa versus the reference product (GONAL-f®, Merck KGaA, Darmstadt, Germany or GONAL-f® RFF; EMD
Serono, Inc., Rockland, MA), have had insufficient power to detect differences in clinically meaningful outcomes
such as live birth.
Methods: Medline, Embase, the Cochrane Library, Web of Science and clinical trial registries were searched for
randomised controlled trials (RCTs) and conference abstracts comparing biosimilar follitropin alfa versus the
reference product in controlled ovarian stimulation (COS) cycles published before 31 October 2020. Only studies in
humans and publications in English were included. Retrieved studies were screened independently by two authors
based on titles and abstracts, and then by full text. Inclusion criteria: RCTs comparing follitropin alfa biosimilar
preparations with the reference product in infertile patients of any age, with any type of infertility for any duration,
undergoing COS for the purposes of MAR treatment (including frozen cycles). The primary outcome was live birth.
Combined data for biosimilar preparations were analysed using a fixed-effects model.
Results: From 292 unique records identified, 17 studies were included in the systematic review, representing five
unique RCTs that were included in the meta-analysis. Rates of live birth (RR = 0.83, 95% CI 0.71, 0.97; 4 RCTs, n =
1881, I2 = 0%), clinical pregnancy (RR = 0.82, 95% CI 0.72, 0.94; 4 RCTs, n = 2222, I2 = 0%) and ongoing pregnancy
(RR = 0.81, 95% CI 0.68, 0.96; 4 RCTs, n = 1232, I2 = 0%) were significantly lower with biosimilar preparations versus
the reference product. Rates of cumulative live birth and cumulative clinical pregnancy were also significantly lower
with biosimilars versus the reference product. There was high risk of publication bias.
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Conclusions: This meta-analysis included data from RCTs evaluating the efficacy and safety of the biosimilar
follitropin alfa preparations and demonstrated lower probability of live birth and pregnancy (ongoing and clinical)
in couples treated with biosimilar preparations compared with the reference product. This study provides more
insight into the differences between biosimilar r-hFSH preparations and the reference product than previously
reported.
Trial registration: Registration number: CRD42019121992.
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Background
Exogenous gonadotrophins are used to treat infertility
by inducing ovulation or by stimulating multifollicular
development in women undergoing medically assisted
reproduction (MAR) treatment [1]. The reference prod-
uct recombinant human follicle-stimulating hormone (r-
hFSH, follitropin alfa) was first approved in Europe in
1995 (GONAL-f®, Merck KGaA, Darmstadt, Germany)
[2] and in the USA in 1997 (GONAL-f® RFF; EMD Ser-
ono, Inc., Rockland, MA) [3] for the induction of multi-
follicular development in women undergoing MAR
treatment. With a predicted 19,245,492 cumulative treat-
ment cycles in women to date (calculated from expected
average use per treatment cycle and sales data [4]) and a
reported mean live birth rate of 21.7% [5, 6]), more than
4 million babies are estimated to have been born follow-
ing treatment with GONAL-f®.
Biosimilar preparations, defined as biological medicinal
products that contain a version of the active substance
of an already authorised original biological medicinal
product (reference medicinal product) [7], are also avail-
able for follitropin alfa from different marketing
authorization holders. According to the European Medi-
cines Agency (EMA), the similarity to the reference me-
dicinal product needs to be established in terms of
quality characteristics, biological activity, safety and
efficacy based on comprehensive comparability studies
before it can be approved for use [7, 8]. Ovaleap® (Ther-
amex, Ireland; launched in 2013) [9, 10] and Bemfola®
(Gedeon Richter PLC, Hungary; launched in 2014; also
known as Afolia in NCT01687712 and NCT01121666)
[11–13] were approved in the EU based on Phase III
clinical trials demonstrating non-inferiority to the refer-
ence product GONAL-f® for number of oocytes retrieved
and comparable safety. Primapur® (iVFarma, LLC,
Russia) is due to be launched in Russia but, as there
were no requirements for the study primary endpoint
set by the Ministry of Health of the Russian Federation,
Primapur® was approved based on a clinical study asses-
sing the same endpoint defined by the EMA, which was
number of retrieved oocytes [14]. The biosimilar Folli-
trope® (LG Chem, Ltd., South Korea) has been on the
market since 2006 and is available in Asian countries,
including China, South Korea, Thailand and Vietnam
[15–17]. However, due to the lack of publicly available
information regarding the approval of Follitrope®, it is
not clear which primary endpoint/clinical outcome was
considered for the marketing authorisation approval.
Live birth has been increasingly identified as the
standard clinical approach to measure the success of
infertility treatment [18–20] and there is increasing
consensus that ongoing pregnancy is usually well cor-
related with live birth [21–23]. Since regulatory ap-
proval of biosimilar preparations is governed by a
distinct pathway which varies between countries, it is
important from a physician and patient perspective to
consider all available evidence to evaluate if clinically
meaningful differences exist in quality, safety, or effi-
cacy outcomes after use of biosimilar preparations in
comparison with the reference product [24–26]. Spe-
cifically, for different gonadotrophin preparations used
in MAR, the evidence regarding efficacy of biosimilar
r-hFSH preparations in terms of live birth or ongoing
pregnancy outcomes should be assessed and taken
into account, together with the evidence from studies
assessing surrogate outcomes [21, 27, 28].
The Phase III clinical trials used for marketing au-
thorisation approval, comparing the biosimilars Bem-
fola® [11], Ovaleap® [10] and Primapur® [14] with the
reference product, also assessed live birth rates as
well as ongoing and clinical pregnancy outcomes.
However, as these were not primary endpoints of the
studies, the analyses were not powered to detect dif-
ferences in these outcomes [29]. Systematic reviews
and meta-analyses are widely accepted methodologies
for synthesizing evidence from trials regarding specific
research question. Since there is no limitation regard-
ing the type of outcome (primary or secondary) that
can be extracted from the original study and analysed,
systematic reviews and meta-analyses can be superior
to other types of studies in terms of the patient num-
ber available for the analysis and the power to detect
differences in relevant outcomes [30].
With this in mind, the aim of this meta-analysis was to
investigate whether there were any differences in live
birth, clinical and ongoing pregnancy rates between
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biosimilar preparations of follitropin alfa and the refer-
ence product using data from published randomised con-
trolled trials (RCTs) and from other credible data
sources, in order to provide a comprehensive analysis
that takes into account all available evidence.
Materials and methods
Study protocol
The study was conducted and reported according to the
Preferred Reporting Items for Systematic Reviews and
Meta-Analyses (PRISMA) Guidelines (http://www.
prisma-statement.org/). A protocol for the systematic
review was registered in The International Prospective
Register of Systematic Reviews (PROSPERO;
CRD42019121992) prior to quantitative analysis.
Literature searches
Electronic databases (MEDLINE, Embase, Cochrane Li-
brary and Web of Science, US Food and Drug Adminis-
tration [FDA] and EMA) and clinical trial registries
(ClinicalTrials.gov and the World Health Organization
[WHO] international clinical trial registry platform)
were searched for RCTs and conference abstracts com-
paring biosimilar follitropin alfa preparations with the
reference product, published up to 31 October 2020.
The search strategy comprised key words/terms and
database-specific indexing terminology on biosimilar
preparations of r-hFSH and the reference product (Sup-
plementary Table 1). The literature search results were
filtered to only include studies in humans, publications
in English and to remove any duplicates.
Study selection
The studies retrieved by the literature search were se-
quentially screened for inclusion independently by two
authors (SJ and AS) based on titles and abstracts and
then by full text.
Inclusion criteria, as defined in protocol for systematic
review (CRD42019121992), were: RCTs comparing folli-
tropin alfa biosimilar preparations with the reference
product in infertile patients of any age, with any type of
infertility for any duration, undergoing controlled ovar-
ian stimulation (COS) for the purposes of MAR treat-
ment (including frozen cycles). Only trials in which all
aspects of the in vitro fertilisation (IVF) protocols for
both treatment arms were the same (except for the use
of different r-hFSH preparations: biosimilar preparations
versus the reference product), were considered [21].
Crossover trials were included; however, only data for
the period of the study before the crossover occurred
(e.g. only data from the first cycle) were considered for
analysis. RCTs with asymmetric co-interventions be-
tween treatment arms, non-randomised studies, cohort
studies, case–control studies, case-series, case reports
and any studies evaluating drugs for ovarian stimulation
other than follitropin alfa biosimilar preparations or the
reference product (e.g., follitropin beta, urinary FSH)
were excluded. The authors of this review were not
blinded to the authors or author institutions of the in-
cluded RCTs.
Data collection
The main characteristics of the included studies were in-
dependently assessed and extracted by two authors AS
and SJ into a predefined standard data extraction form
(Supplementary Tables 2 and 3) and any disagreement
was solved by CAV. Outcomes of (pre-specified)
interest were details of treatment protocols used and
primary and secondary endpoints of included studies
(Supplementary Table 4). In accordance with the
Cochrane Handbook for Systematic Reviews of Inter-
ventions [30], in the case when the data relevant to
the analysis were not available in the published re-
port, attempts were made to contact the authors of
the individual studies, or data from other credible
sources (e.g., trial registries) were used to extract
complete dataset.
Risk of bias and overall quality of evidence
Risk of bias of individual studies was assessed inde-
pendently by two reviewers (AS and SJ) using the
Cochrane risk of bias tool 2.0 for randomised trials
[31]. The overall quality of the evidence was graded
according to the Grading of Recommendations As-
sessment, Development and Evaluation (GRADE)
Working Group guidelines [32].
Endpoints for meta-analysis
The primary endpoint of the meta-analysis was live birth
rate per randomised patient. This was defined as the
number of deliveries with at least one live birth resulting
from one initiated or aspirated treatment cycle, includ-
ing all cycles in which fresh and/or frozen embryos are
transferred, until one delivery with a live birth occurs or
until all embryos are used, whichever occurs first. The
delivery of a singleton, two or other multiples were reg-
istered as one delivery [33]. Only data from the first
cycle were used for this endpoint.
Secondary outcomes were clinical pregnancy rate, on-
going pregnancy rate, total dose of gonadotrophins, dur-
ation of ovarian stimulation, number of oocytes
retrieved per aspirated cycle and number of embryos ob-
tained per aspirated cycle, moderate or severe ovarian
hyperstimulation syndrome (OHSS) rate, miscarriage
rate, ectopic pregnancy rate, multiple pregnancy rate
and immunogenicity (measured by the titres of anti-FSH
antibodies). Only moderate or severe OHSS were in-
cluded in the analysis, as these were considered clinically
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relevant, and were as defined by the investigators for the
eligible individual studies. Clinical pregnancy, miscar-
riage, ectopic pregnancy and multiple pregnancy were as
defined by The International Glossary on Infertility and
Fertility Care, 2017 [33]. Ongoing pregnancy was defined
as clinical pregnancy at 10–12 weeks. All endpoints were
evaluated per randomised patient, with some endpoints
(live birth rate, clinical and ongoing pregnancies) also
assessed cumulatively. Cumulative live birth was defined
as the number of deliveries with at least one live birth,
expressed per 100 patients, after a specified time and fol-
lowing all treatments over multiple stimulation cycles.
Statistical analysis
All data extracted were analysed using the intention-to-
treat principle. Pairwise meta-analyses were performed
using the fixed-effects model with the Mantel–Haenszel
method. In accordance with the Cochrane guidance on
Systematic Reviews [34], this review aimed to address
the broad question on whether there were any differ-
ences in reproductive outcomes after COS with biosimi-
lar follitropin alfa preparations versus the reference
product. To this end, data relevant for the experimental
intervention (biosimilar preparations) group were com-
bined into a single group and compared with the com-
bined data for the comparator intervention (reference
product) group during the analysis. This approach has
been widely used in meta-analyses to generate clinical
evidence comparing different classes of gonadotrophins
used for COS in assisted reproductive technology (ART)
treatment [5, 35–41]. Recently, the ESHRE guideline on
COS have used these “broad scope” systematic reviews
and meta-analyses as first line evidence to elaborate the
clinical practice guideline recommendations [42].
The effect size for dichotomous outcomes was pre-
sented as relative risk (RR). Uncertainty was expressed
using 95% confidence intervals (CI). For continuous
data, mean difference was used. Statistical heterogeneity
was evaluated with the I2 statistic (I2 > 50% was indica-
tive of significant heterogeneity). A Funnel plot was used
if at least 10 eligible publications were found, to detect
publication bias. A sensitivity analysis for the primary
endpoint was performed as a random-effects meta-
analysis for all comparisons with the exclusion of study
with an unclear method of randomisation.
Results
Characteristics of the included RCTs
Of the 292 unique publications initially identified, 17
studies were included in the systematic review, which
reported data from five unique RCTs (NCT01121666,
ISRCTN74772901, NCT01687712, NCT03088137,
NCT03506243) (Supplementary Figure 1). The biosi-
milar preparations investigated were Bemfola® (also
known as Afolia; two RCTs) [11–13], Ovaleap® [10], Pri-
mapur® [14] and Follitrope® [17]. For the RCT
NCT01121666, the data were obtained from the publica-
tion by Rettenbacher et al. (2015) [11] and from the
EMA Assessment report [12]. For the RCT investigating
Ovaleap®, data from the first cycle and subsequent cycles
were obtained from separate publications [10, 43]; how-
ever, data from the subsequent cycles were not utilised,
as all participants crossed over to the exclusive use of
Ovaleap® [43].
The main characteristics of the RCTs included in the
meta-analysis are summarised in Supplementary
Table 2. Inclusion criteria were generally heterogeneous;
however, all five RCTs excluded women with a history
of poor response. The RCT investigating Follitrope® ex-
cluded patients who had previous history of any type
OHSS and the other four studies excluded those who
previously had severe OHSS (Supplementary Table 3).
Outcomes assessed in the individual RCTs are sum-
marised in Supplementary Table 4. Four studies re-
ported ongoing pregnancy as defined by clinical
pregnancy at 10–12 weeks [10, 11, 14, 17], and three
studies reported on clinical pregnancy confirmed by
ultrasound at 5–8 weeks [10, 11, 13]. In the Ovaleap®
study, four patients who did not achieve pregnancy after
first embryo transfer became pregnant after receiving
frozen embryos. As a result, in the Ovaleap® study the
clinical pregnancy rate was reported separately for only
fresh (43/153 in the Ovaleap® group and 52/146 in the
GONAL-f® group) or fresh and frozen (46/153 Ovaleap®
and 53/146 GONAL-f®) embryo transfer cycles. For the
combined analysis, we used the clinical pregnancy rates
reported for only fresh embryo transfer cycles. The take-
home baby rates, however, were reported for both fresh
and frozen cycles combined in the Ovaleap® study; there-
fore, the combined analysis of live birth rate including
only fresh embryo transfer cycles was not possible. Only
severe OHSS was reported in two studies, while moder-
ate cases were not reported [14, 17].
The assessment of risk of bias was evaluated as having
“some concerns” in two of the RCTs [13, 14]. The
method of randomisation and allocation concealment
was not reported for one RCT investigating Bemfola®/
Afolia (NCT01687712) [13], making it difficult to evalu-
ate the quality of the reported findings; therefore, the
evidence for primary and secondary endpoints was
graded as moderate for this RCT. The RCT investigating
Primapur® (NCT03088137) [14] calculated a power cut-
off of 80%, resulting in a smaller sample required to de-
tect equivalence in the number of oocytes retrieved with
biosimilar preparations and the reference product. Fur-
thermore, in the RCT evaluating Follitrope® [17], live
birth rate was not evaluated, and there was a high attri-
tion after treatment allocation, with only 55% (186/339)
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of patients allocated to Follitrope® and 71% (79/112) of
patients allocated to GONAL-f® receiving an embryo
transfer, due to high cancellation rates (44% and 28%, re-
spectively). In addition, per protocol analysis was per-
formed but the deviations from the intended
interventions were not reported in the article, and the
protocol was not available prior to the study being pub-
lished, resulting in the study being evaluated as having
high risk of bias [17]. Only data from the first cycle of
the RCT investigating Ovaleap® [10] were included in
the cumulative analysis; therefore, the evidence for cu-
mulative endpoints was graded as low. The correspond-
ing authors of the studies included in this meta-analysis
were contacted to obtain additional information on the
method of randomisation, IVF protocol and fertility out-
comes for Bemfola®/Afolia RCT (NCT01687712) [13]
and the immunogenicity data for the RCT investigating
Ovaleap® [10]; however, no replies were received. The
live birth outcome measurement was deemed as having
low risk of bias for four RCTs included in this analysis.
Protocol deviations and missing outcomes were ad-
dressed by comparing intention-to-treat and as-treated
analyses. This was not possible with the Follitrope®
study, as only per protocol analysis was reported [17].
Comparison with previously published protocols and
trial registries did not reveal reporting bias, with the ex-
ception of the study investigating Follitrope® [17]. Given
the small number of eligible RCTs, publication bias was
not assessed; however, this was likely to be of concern as
other biosimilar trials registered in trial registries were
detected in the search strategy, which were lacking full
publication of results [44–49] (Supplementary Table 5).
The authors of these registered trials were also contacted
to obtain further information; however, they did not
respond.
Primary endpoint
Live birth rate was significantly lower with biosimilar
preparations (Bemfola®, Ovaleap® and Primapur®) versus
the reference product (GONAL-f® or GONAL-f® RFF)
(RR 0.83, 95% CI 0.71, 0.97; 4 RCTs, n = 1881, I2 = 0%,
moderate quality evidence, Fig. 1). The sensitivity ana-
lysis, which excluded the RCT with an unclear
method of randomisation [13], did not alter the effect
size, however, it increased the uncertainty around this
estimate resulting in a non-statistically significant
finding (RR 0.83, 95% CI 0.68, 1.03; 3 RCTs, n = 781,
I2 = 0%, moderate quality evidence, Supplementary
Figure 2).
Secondary endpoints
The secondary analyses of the combined data for biosi-
milar preparations resulted in significantly lower clinical
pregnancy rate and ongoing pregnancy rate observed
with biosimilar follitropin alfa preparations compared
with the reference product, while the evidence for OHSS
rate was inconclusive (Fig. 2). In addition, there was in-
sufficient evidence for a difference in the total dose of
gonadotrophins; however, a significantly higher number
of oocytes was retrieved and a significantly shorter dur-
ation of ovarian stimulation was observed with biosimi-
lar preparations versus the reference product (Fig. 3).
Analyses of the cumulative data showed a lower cumula-
tive live birth rate and clinical pregnancy rate observed
with biosimilar follitropin alfa preparations versus the
reference product, while there was insufficient evidence
for a difference in cumulative ongoing pregnancy rate
(Fig. 4).
The evidence on ectopic pregnancy rate (RR 1.16, 95%
CI 0.39, 3.43; 3 RCTs, n = 1509, I2 = 0%, moderate qual-
ity evidence) and multiple pregnancy rate (RR 1.34, 95%
CI 0.61, 2.94; 2 RCTs, n = 409, I2 = 0%, moderate quality
evidence) was inconclusive. Miscarriage rate (foetal loss
prior to 22 weeks of gestation [33]) was not available for
all studies and was difficult to estimate, as pregnancy up
to 22 weeks was not reported in all of the studies. Im-
munogenicity and the number of embryos obtained were
not evaluated in this meta-analysis, owing to a lack of
data or heterogeneity in the methods used to assess
these outcomes.
Discussion
This meta-analysis included data from the Phase III clin-
ical trials evaluating respective biosimilar follitropin alfa
preparations in the EU, USA, Russia and China, and
demonstrated lower probability of live birth, ongoing
and clinical pregnancy in couples treated with biosimilar
preparations compared with the reference product.
Available data from up to three cycles allowed the evalu-
ation of cumulative outcomes, which showed lower cu-
mulative live birth and clinical pregnancy rates for
biosimilar preparations versus the reference product.
Safety data suggested that biosimilar preparations had a
similar risk of OHSS, ectopic pregnancy and multiple
pregnancy compared with the reference product.
Our findings show that although the number of oo-
cytes retrieved was slightly higher (one more egg in all
studies, except in the Follitrope® study reporting two
more eggs), lower pregnancy rates were reported with
biosimilar preparations versus the reference product. To
investigate this further, we conducted an additional ana-
lysis which excluded the Follitrope® study [17], which
was identified as having a high risk of bias. The exclu-
sion of the Folitrope® study from the analysis resulted in
insufficient evidence for a difference in the number of
oocytes retrieved with GONAL-f® versus biosimilars
(mean difference 0.20, 95% CI -0.41, 0.81; 4 RCTs; n =
1881; I2 = 0%, moderate quality evidence). This finding
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should therefore be interpreted with caution. Further-
more, the mean total number of eggs varied between 10
and 15 in the five RCTs considered (Fig. 3b), which are
normal numbers expected from a population with a nor-
mal ovarian reserve receiving a 150 – 225 IU r-hFSH
starting dose [2, 50–52]. Therefore, this observation is
not in conflict with current opinion that the number of
oocytes retrieved positively correlates with downstream
fertility treatment outcomes, including pregnancy and
live birth [50–58].
It is common to see comparability studies for infertility
medications adopting the number of retrieved oocytes as
a primary (surrogate) endpoint, as this avoids the impact
of confounding factors that might not be attributable to
these medications, and it is also more economical [59].
Nonetheless, there are several other factors that can have
an impact on the success of IVF treatment, such as the
quality of the oocytes, embryos [60] and the endomet-
rium [61]. Previous studies have shown that there are
differences in biological activity, composition of iso-
forms, glycosylation patterns and clearance rates ob-
served between different preparations of r-hFSH [8, 29].
This may affect their mode of action on FSH receptors
in the ovary and therefore have an impact on the quality
of oocytes [8, 29]. It is also important to note that the
assessment of oocyte and embryo quality is often hetero-
geneous, with different oocyte and embryo grading sys-
tems used across different clinics, which makes inter-
laboratory and inter-study comparisons extremely diffi-
cult [62]. The implementation of a unified objective ap-
proach to assess the quality of oocytes and embryos
across different clinics is therefore required before fair
comparisons can be made to evaluate the effectiveness
of different treatment options.
Choosing between biosimilar preparations and the ref-
erence product can prove challenging. We believe that
the decision regarding whether to use biosimilar prepa-
rations or the reference product should be reserved to
the treating physician, based on clinical efficacy and
safety characteristics, real-world effectiveness, cost-
effectiveness studies and patient preference [8]. There is
still a debate with regard to using surrogate endpoints to
measure the success of infertility treatment, due to the
fact that they do not capture the effect of the treatment
on clinically relevant outcomes [63]. Although one treat-
ment option can appear to be equally effective in terms
of midway (upstream) outcomes — such as number of
oocytes retrieved — the ultimate goal of fertility treat-
ment is pregnancy leading to live birth. While the stud-
ies evaluating midway (upstream) fertility treatment
outcomes to compare treatment options are scientifically
valid, they fail to answer the ultimate question of
whether the treatments are comparable in terms of live
birth. It has been confirmed in the ESHRE Guideline for
Ovarian Stimulation in IVF/ICSI and in the International
Committee for Monitoring Assisted Reproductive Tech-
nology (ICMART) revised glossary that the most rele-
vant outcomes of infertility treatment are live birth rate
and cumulative live birth rate [33, 42]. Studies should
therefore aim to evaluate these endpoints in order to
measure the comparability between r-hFSH biosimilar
preparations and the reference product.
Fig. 1 Relative risk for live birth rate with biosimilar preparations of follitropin alfa versus the reference product
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A recent meta-analysis by Budani et al. [64] evaluated
a range of efficacy outcomes with Bemfola®, Ovaleap®
and Primapur® biosimilar preparations (n = 457 women
in total) versus the reference product GONAL-f (n =
324), based on the data from the same three RCTs that
were included in our meta-analysis [10, 11, 14].
Fig. 2 Relative risk for clinical pregnancy rate (a), ongoing pregnancy rate (b) and ovarian hyperstimulation syndrome (c) with biosimilar
preparations of follitropin alfa versus the reference product
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Although a significantly lower clinical pregnancy rate
was seen with the biosimilar preparations compared with
the reference product (odds ratio 0.71, 95% CI 0.52,
0.97), no difference was reported for take-home baby
rate or other outcomes of interest [64]. This may be due
to insufficient power to detect differences in these
outcomes, as the analysis by Budani et al. was restricted
to only three published RCTs, thus limiting the number
of patients included in the analysis.
Compared to the meta-analysis by Budani et al. [64],
our meta-analysis included a higher number of patients,
which allowed evaluation of treatment effects on the
Fig. 3 Mean difference in total dose of gonadotrophins (a), number of oocytes retrieved (b) and duration of ovarian stimulation (c) with
biosimilar preparations of follitropin alfa versus the reference product
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outcome of interest with a greater statistical power. In
addition, we have included the data reported in the
Phase III trial of Follitrope® versus GONAL-f®, which
was not included in the analysis by Budani et al.
Although Follitrope® was not defined as a biosimilar to
follitropin alfa in the publication [17]; after appropriate
assessment of local registration procedure, it was
confirmed that Follitrope® is a biosimilar of GONAL-f®
Fig. 4 Relative risk for cumulative live birth rate* (a), cumulative clinical pregnancy rate (b) and cumulative ongoing pregnancy rate (c) with
biosimilar preparations of follitropin alfa versus the reference product. *For the cumulative live birth, only data from the first cycle could be used
for the RCT investigating Ovaleap® as all participants crossed over to the exclusive use of Ovaleap® in subsequent cycles
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[15–17, 65]. Furthermore, in accordance with Cochrane
guidance on Systematic Reviews, we have considered
data from all credible sources related to the selected
RCTs, including clinical trial databases and regulatory
documents [30]. This extended dataset enabled us to re-
port on cumulative endpoints, which would not be pos-
sible taking into account only the data reported in RCT
publications, which, by design, are often limited to a
pre-specified and narrow timeframe.
The populations assessed in the individual RCTs in-
cluded in our meta-analysis mostly consisted of young,
good-prognosis couples with normal response to go-
nadotrophin treatment, which poorly reflects the overall
population of patients that are actually treated at infertil-
ity clinics. To provide the full picture in terms of com-
parability of r-hFSH biosimilars to the reference
product, we recommend that further RCTs and also
real-world data analyses should be conducted to assess
other patient populations that are treated during routine
clinical practice. This includes older patients, those with
a poor or high response to ovarian stimulation and pa-
tients with repeated IVF failures. Such studies should
also aim to compare cumulative outcomes, to account
for the need for multiple ART cycles and the potential
differences between patients undergoing their first cycle
and those treated in subsequent cycles after they did not
have a pregnancy leading to live birth in previous at-
tempts [19].
More studies are required to assess the comparative
effectiveness of biosimilar preparations in terms of clin-
ically meaningful MAR outcomes in a real-world setting.
It has been argued that analysis of data from large obser-
vational databases can be complementary to data ana-
lysis from RCTs when investigating and comparing the
effectiveness of different MAR treatment options. Real-
world studies can include a large number of patients and
treatment cycles, representing the reality of clinical prac-
tice, and need to take into account the baseline and
treatment confounders associated with this heteroge-
neous population, to evaluate if clinically meaningful dif-
ferences in live birth rates exist between different MAR
treatment options [66–69]. Furthermore, RCTs often
have a limited follow-up time, therefore making assess-
ment of outcomes, such as live birth, challenging. In
contrast, real-world data studies can allow a longer
follow-up, including assessment of live birth data, as well
as obstetrical and neonatal data, thus providing add-
itional information about long-term effectiveness of a
medication. Finally, as there are differences in the costs
associated with biosimilar follitropin alfa preparations
versus the reference product used during ovarian stimu-
lation, cost-effectiveness studies should be conducted in
order to make informed decisions from a health eco-
nomics perspective.
One of the strengths of our meta-analysis was that the
data analysed for the primary outcome collectively com-
prised 1881 patients, which is a sufficient number for
hypothesis generation. To increase the number of pa-
tients available for the quantitative analysis, we have
combined the data for the respective biosimilar prepara-
tions in the experimental intervention group for com-
parison with the reference product, in accordance to
Cochrane Handbook for Systematic Reviews of Interven-
tions [34] and other systematic reviews/meta-analyses
where outcomes were not reported according to individ-
ual gonadotrophin preparations [5, 35–41]. The protocol
for this systematic review, including the study objectives,
pre-defined inclusion and exclusion criteria and planned
analyses, was registered in PROSPERO prior to literature
search being conducted. As such, the design of quantita-
tive analysis was not, a priori, affected by the results of
individual trials included in this study. Finally, there was
generally a low level of heterogeneity among the studies
for most of the outcomes.
This study had some inherent limitations. Only a small
number of studies were included in this meta-analysis,
and most participants (n = 1100) originated from a single
large RCT investigating Bemfola®/Afolia [13], which was
evaluated as having some concerns for the risk of bias as
no information was reported on the methods used for
randomisation and allocation concealment. However, in
our opinion, as this Bemfola®/Afolia RCT was conducted
for marketing authorisation approval purposes usually
associated with stringent quality criteria, this clinical
trial was likely of a high quality, with a detailed study
protocol and data analysis plan, despite the lack of pub-
licly available information on randomisation and alloca-
tion concealment. Four frozen embryo cycles originating
from one study [10] were included in the combined ana-
lysis for live birth, which may have affected the compari-
son between biosimilars and the reference product for
this outcome. Furthermore, the included studies com-
pared outcomes for only four biosimilar preparations
with the reference product. There are several other bio-
similar gonadotrophin preparations available on the
market; however, the data either remain unpublished or
the studies identified did not assess the fertility out-
comes of interest (Supplementary Table 5) and at-
tempts to obtain more information from the authors
were unsuccessful. This indicates a need for more head-
to-head studies to evaluate the possible differences in
outcomes among all follitropin alfa preparations. The
evidence for cumulative data was judged as low quality,
as crossover occurred after the first cycle in the study in-
vestigating Ovaleap®; therefore, only data from the first
cycle were included from this study. In addition, patients
often discontinued ART treatment during subsequent
cycles due to non-medical reasons (e.g. funding, burden
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of treatment), and while an attempt was made to accom-
modate this by using an intention-to-treat analysis, this
was not possible for the Follitrope® study, and there is
still risk of bias in the other studies as well. Moreover,
women with severe OHSS were excluded from add-
itional cycles, and women who did not achieve live birth
in the first cycle were offered subsequent ART treatment
cycles.
Conclusions
This meta-analysis suggests that treatment with biosimi-
lar preparations of follitropin alfa is likely to result in
lower probability of live birth, clinical and ongoing preg-
nancy compared with the reference product. Safety data
showed that biosimilar preparations carried a similar risk
of OHSS, ectopic pregnancy and multiple pregnancy
compared with the reference product. More head-to-
head RCTs as well as real-world studies are required to
ascertain clinically relevant fertility outcomes, including
cumulative pregnancy and live birth rates.
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